Initiator Pharma A/S

Stockholm Stock Exchange INIT.ST

Initiator Pharma A/S Operating Income for the year ending December 31, 2023: USD -4.00 K

Initiator Pharma A/S Operating Income is USD -4.00 K for the year ending December 31, 2023, a 99.93% change year over year. Operating income is the profit earned by a company from its normal business operations before interest and taxes are deducted.

Initiator Pharma A/S Operating Income for the year ending December 31, 2022 was USD -5.99 M, a -69.86% change year over year.
Initiator Pharma A/S Operating Income for the year ending December 31, 2021 was USD -3.53 M, a -104.43% change year over year.
Initiator Pharma A/S Operating Income for the year ending December 31, 2020 was USD -1.72 M, a -23.38% change year over year.
Initiator Pharma A/S Operating Income for the year ending December 31, 2019 was USD -1.40 M, a 27.83% change year over year.

Key data

Date	Operating Income	EBIT	EBITDA	Net Income

Stockholm Stock Exchange: INIT.ST

Initiator Pharma A/S

CEO	Dr. Claus Elsborg Olesen
IPO Date	March 16, 2017
Location	Denmark
Headquarters	Ole Maaloes vej 3
Employees	3
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. It develops IP2018, a monoamine reuptake inhibitor for the treatment of psychogenic erectile dysfunction; IPED2015 to treat patients suffering from organic erectile dysfunction; and IPTN2021 for targeting an orphan drug indication in severe neuropathic pain. The company's pre-clinical stage candidates include IPNP2015 for the treatment of chronic pain; and IPDP2015 for depression. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark.

Key trends

Past 5 years